MedTrace Logo

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

NCT00724334 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-03-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

Conditions

Interventions

DRUG

SAR302503 (TG101348)

orally administered, once a day

Sponsors & Collaborators

Principal Investigators

  • Ayalew Tefferi, MD · Mayo Clinic, Rochester, MN

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00724334 on ClinicalTrials.gov